Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced that preclinical data from its lead ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ...
We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and technical operations across modalities, specifically in allogenic cell ...